Tu banner alternativo

Selonabant

In this article, we will delve into the world of Selonabant to explore its many facets and discover its importance in different contexts. Throughout history, Selonabant has played a fundamental role in people's lives, impacting the way we relate, work and function in society. From its origins to its relevance today, Selonabant has been the subject of study and debate, generating endless interpretations and opinions. Through this article, we propose to analyze and reflect on Selonabant, unraveling its most relevant aspects and offering a critical and comprehensive look that allows us to understand its true scope.

Tu banner alternativo

Selonabant
Clinical data
Other namesANEB-001; ANEB001; V-24343; V24343
Drug classCannabinoid receptor antagonist; Cannabinoid CB1 receptor antagonist; Cannabinoid antidote
Identifiers
  • N-tert-butyl-3-methoxy]azetidine-1-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H24ClF3N2O2
Molar mass440.89 g·mol−1
3D model (JSmol)
  • CC(C)(C)NC(=O)N1CC(C1)O(C2=CC=C(C=C2)Cl)C3=CC=CC=C3C(F)(F)F
  • InChI=1S/C22H24ClF3N2O2/c1-21(2,3)27-20(29)28-12-16(13-28)30-19(14-8-10-15(23)11-9-14)17-6-4-5-7-18(17)22(24,25)26/h4-11,16,19H,12-13H2,1-3H3,(H,27,29)/t19-/m1/s1
  • Key:BNLYOVHLLDBOFZ-LJQANCHMSA-N

Selonabant (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ANEB-001, V-24343) is a cannabinoid CB1 receptor antagonist which is under development for the treatment of acute cannabinoid intoxication.[1][2][3] It was also previously being developed to treat obesity, but development for this indication was discontinued.[1] The drug is administered by intravenous infusion.[1] It dramatically reduced the subjective effects of Δ9-tetrahydrocannabinol (THC) in a clinical trial.[3] Selonabant is being developed by Vernalis and Anebulo Pharmaceuticals.[1][2] As of December 2024, it is in phase 2 trials.[1][2]

See also

References

  1. ^ a b c d e "Anebulo Pharmaceuticals". AdisInsight. 26 December 2024. Retrieved 25 February 2025.
  2. ^ a b c "Delving into the Latest Updates on Selonabant with Synapse". Synapse. 23 January 2025. Retrieved 25 February 2025.
  3. ^ a b Gorbenko AA, Heuberger JA, Juachon M, Klaassen E, Tagen M, Lawler JF, et al. (February 2025). "CB1 Receptor Antagonist Selonabant (ANEB-001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial". Clinical Pharmacology and Therapeutics. 117 (5): 1427–1436. doi:10.1002/cpt.3581. PMC 11993283. PMID 39898464.
Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia